Sinovac Biotech

Sinovac Biotech Ltd. is a holding company, which engages in the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. Its product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza, H1N1 influenza, and mumps. The company was founded in 1993 and is headquartered in Beijing, China.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that the inactivated COVID-19 vaccine candidate developed by Sinovac Life Sciences (Sinovac LS), or “CoronaVac”, was approved by the National Medical Products Administration (NMPA) for clinical trial in adolescents and children in August 10th, 2020. This randomized, double-blinded, and placebo-controlled phase I/II clinical trial am

Sinovac’s Coronavac™, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase I/II Clinical Trial in Adolescents and Children

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it has recently commenced phase III clinical trials for its inactivated COVID-19 vaccine candidate developed by Sinovac Life Sciences (Sinovac LS), or “CoronaVac,” in Turkey. The phase III clinical trial seeks to test efficacy and safety of CoronaVac in Turkey and aims to be a pivotal study to support the licensure of this pro

Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey

Sinovac Biotech has plans to expand the clinical trial of its COVID-19 vaccine trial to children and adolescents later this month.

Sinovac Plans To Expand COVID-19 Vaccine Trials To Children And Adolescents

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced that the inactivated COVID-19 vaccine candidate developed by Sinovac Life Sciences (Sinovac LS), or “CoronaVac,” shows good safety and immunogenicity on healthy adults aged 60 and above from its phase I/II clinical studies conducted in China, which is comparable to the result in healthy adults aged from 18 to 59 in the earlier studies.

Sinovac Reports Preliminary Phase I/II Results of COVID-19 Vaccine in Elderly Volunteers

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the second quarter ended June 30, 2020.

Sinovac Reports Unaudited Second Quarter 2020 Financial Results

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it has signed two agreements in Hainan, China with PT Bio Farma, a leading biopharmaceutical company in Indonesia, for the supply, local production and technology licensing in respect of the CoronaVac, Sinovac’s inactivated vaccine candidate against COVID-19.

Sinovac Signs Agreement with Bio Farma Indonesia for COVID-19 Vaccine Cooperation

AstraZeneca

BioNTech SE

Moderna

Novavax

Pfizer

GlaxoSmithKline

Inovio Pharmaceuticals

Leaders and laggards in the COVID-19 vaccine race -- and how likely they are to win approval.

Here Are All the COVID-19 Vaccines Currently in Clinical Testing

The World Health Organization this week said 21 candidate vaccines are in clinical trials at the moment, meaning they are being tested on human volunteers.

Pharma industry balancing accessibility and intellectual property rights in coronavirus vaccine race

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. ( “Sinovac” or the “ Company”)(Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced an update to its previously announced partnership with Butantan, a leading Brazilian producer of immunobiologic products and vaccines. On July 3, 2020, the Brazilian National Regulatory Agency, Anvisa, granted approval to a phase III clinical trial sponsored by Instituto Butantan to test efficacy and safety of the inactivated COVI

Sinovac COVID-19 Vaccine Collaboration with Butantan Receives Approval from Brazilian Regulator for Phase III Trial

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the first quarter ended March 31, 2020. First Quarter of 2020 Financial Summary Sales for the first quarter of 2020 were $15.4 million, a decrease of 57.9% from $36.6 million in the prior year period. While operating expenses decreased, net income attributable to common shareholders was impacted

Sinovac Reports Unaudited First Quarter 2020 Financial Results

Johnson & Johnson

Not as quickly as anyone would like, but possibly sooner than some expect.

When Can I Get a Coronavirus Vaccine?

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. ( “Sinovac” or the “ Company”)(Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced the China National Medical Products Administration (or NMPA) issued a product license for its quadrivalent Influenza vaccine (or QIV). Sinovac expects its QIV to be available to the China market for the 2020-2021 influenza season. QIV contains two A strains and two B strains, recommended by the WHO, and the vaccine protects a targ

Sinovac Receives Approval from China for its Quadrivalent Influenza Vaccine

Chinese biopharma Sinovac Biotech, which is one of 10 companies doing human testing of a vaccine candidate for SARS-CoV-2, the virus that causes COVID-19, announced positive preliminary data Monday from Phase 1/2 clinical trials.

News for Sinovac Biotech Stock (SVA)